Literature DB >> 27319129

Quantitative Determination of Vinpocetine in Dietary Supplements.

John M T French, Matthew D King, Owen M McDougal.   

Abstract

Current United States regulatory policies allow for the addition of pharmacologically active substances in dietary supplements if derived from a botanical source. The inclusion of certain nootropic drugs, such as vinpocetine, in dietary supplements has recently come under scrutiny due to the lack of defined dosage parameters and yet unproven short- and long-term benefits and risks to human health. This study quantified the concentration of vinpocetine in several commercially available dietary supplements and found that a highly variable range of 0.6-5.1 mg/serving was present across the tested products, with most products providing no specification of vinpocetine concentrations.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27319129      PMCID: PMC5345962     

Source DB:  PubMed          Journal:  Nat Prod Commun        ISSN: 1555-9475            Impact factor:   0.986


  14 in total

Review 1.  Herbal medicines today and the roots of modern pharmacology.

Authors:  P Goldman
Journal:  Ann Intern Med       Date:  2001-10-16       Impact factor: 25.391

2.  Vinpocetine as a potent antiinflammatory agent.

Authors:  Alexandre E Medina
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-21       Impact factor: 11.205

3.  Mechanism of inhibition of cell proliferation by Vinca alkaloids.

Authors:  M A Jordan; D Thrower; L Wilson
Journal:  Cancer Res       Date:  1991-04-15       Impact factor: 12.701

Review 4.  Pharmacology of nootropics and metabolically active compounds in relation to their use in dementia.

Authors:  C D Nicholson
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

5.  Brain gain: adolescent use of stimulants for achievement.

Authors:  Kim A Noble
Journal:  J Perianesth Nurs       Date:  2012-12       Impact factor: 1.084

6.  Neuroenhancers, addiction and research ethics.

Authors:  David Martin Shaw
Journal:  J Med Ethics       Date:  2012-08-11       Impact factor: 2.903

7.  Phosphodiesterase type 1 inhibition improves learning in rats exposed to alcohol during the third trimester equivalent of human gestation.

Authors:  Claudio C Filgueiras; Thomas E Krahe; Alexandre E Medina
Journal:  Neurosci Lett       Date:  2010-02-26       Impact factor: 3.046

8.  Acute administration of vinpocetine, a phosphodiesterase type 1 inhibitor, ameliorates hyperactivity in a mice model of fetal alcohol spectrum disorder.

Authors:  Fernanda Nunes; Kélvia Ferreira-Rosa; Maurício Dos S Pereira; Regina C Kubrusly; Alex C Manhães; Yael Abreu-Villaça; Cláudio C Filgueiras
Journal:  Drug Alcohol Depend       Date:  2011-09-09       Impact factor: 4.492

9.  Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid.

Authors:  A Kruczynski; J M Barret; C Etiévant; F Colpaert; J Fahy; B T Hill
Journal:  Biochem Pharmacol       Date:  1998-03-01       Impact factor: 5.858

Review 10.  Vinpocetine for cognitive impairment and dementia.

Authors:  S Z Szatmari; P J Whitehouse
Journal:  Cochrane Database Syst Rev       Date:  2003
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.